2015 · 20 citations · 20 references
Open access
PharmacyPharmaceuticsPharmacologyBioavailabilityDrug DeliveryPharmaceutical FormulationDissolution MediaDissolution-controlled ReleaseDrug DissolutionDrug SolubilityOral Bioavailability EnhancementSolubility EnhancementDispersionsDissolution Of Solid DispersionsDissolution Rate OptimizationDrug Release MechanismsMolecular Inclusion ComplexesSolubilitySolubility - Dissolution RelationshipSolubility Determination
The poor solubility and wettability of candesartan cilexetil (CAN) leads to poor dissolution and hence, low bioavailability after oral administration. The aim of this study was to improve the dissolution rate and hence the bioavailability of CAN by preparing solid dispersions (SD)/inclusion complexes (IC) and liquisolid (LS) systems. SD were prepared using polyethylene glycol (PEG) 6000 (hydrophilic polymer) by melting method in different drugto- carrier ratios (1:2, 1:4 weight ratio), while IC (IC1:1 molar ratio) were made with hydroxypropyl-β cyclodextrin (complexing agent) by kneading method. LS systems were prepared using PEG 400 as the nonvolatile solvent, Avicel PH102 as carrier, Aerosil 200 as the coating material. Based on the drug release studies from SDs, SD1:4 was selected to prepare tablets, because it showed an enhanced dissolution profile in comparison with pure drug and SD1:2 according to two-tailed Student’s t-test (p SD1:4 tablets > IC1:1 tablet > marketed tablets. Thus, the SD/IC technique and LS systems can be successfully used for enhancement of the dissolution profile of CAN. Keywords: Candesartan cilexetil, Liquisolid systems, Solid dispirions, Inclusion complexes.
20